Erratum to: Clinical classification of cardiovascular tumors and tumor-like lesions, and its incidences

Errors appeared in the above-cited article. In the Author Biography on the last page of the article, the author’s affiliation should read “Shinshu University School of Medicine”, not “Shinshu University Faculty of Medicine”.


Introduction
Tumors of the cardiovascular system, benign or malignant, are very rare disease, and there are many disorders which do not fit into the concept of tumor or neoplasm; thus, it is very difficult to classify the tumors of the heart and great vessels. As tumors of other organ, tumor of the heart and great vessels are classified as tumors originated from the heart and great vessels, or secondary/metastatic tumor with invasion nearby organs such as lung or metastatic tumors that occur in the distant organ. In addition, tumors originated from the heart are classified by the site of tumor location such as tumor of the heart, cardiac septum, pericardium, or great vessels, and classified by cell type constituting the tumor such as hyperplasia, hamartoma, cyst, or benign or malignant, and also classified by histological features such as mesenchymal, epithelial, and serous membrane (mesothelium). However, there is no established standard method of classification of tumors of the heart and great vessels up to now. In this review, we propose a new clinical classification for tumors of the cardiovascular The review was submitted at the invitation of the editorial committee. system, and summarize its epidemiology and incidence from the reported literatures and our own study.

Classification of tumors of the heart and great vessels
Tumors originated from the heart and great vessels are found at an incidence of about 0.02 % of autopsy. Among these cardiovascular tumors, 70 % of these tumors and most of the surgically excised tumors are benign [1]. Since there is no counterpart tumor in other organs or lack of histogenetical and pathological evidence of true tumor for papillary fibroelastoma, histiocytoid cardiomyopathy, lipomatous hypertrophy of the interatrial septum or cystic tumor of atrioventricular node, and others, pathological classification is very difficult for these tumors [2]. And also, it seems difficult to classify the tumors by histological type, because there are many tumors whose origin is not clear like tumors appear in other organs and tissues. A typical example is that in cardiac myxoma, origin of cardiac myxoma and tumor characteristics is not yet elucidated, and it contains various cell components like epithelium, endothelium, nerve, and undifferentiated mesenchyma which potentially differentiate into many tissues such as blood vessels, glandular structures, bones, and foci of extramedullary hematopoiesis [3]. Also, sarcoma is a malignant cardiovascular tumor, and despite very low incidence, many types of sarcomas which found in other organs were reported in the literatures [4]. However, there is so-called undifferentiated sarcoma exists that cannot determine a certain tendency to differentiate into cells or tissues even if using the latest diagnostic technology such as immunohistochemistry, electron microscopy and genetic analysis [5].
Because there are many cardiac tumors whose origin is not yet determined and cell differentiation was not elucidated, it is very difficult to systematically classify these tumors. According to the well-known classification of ''tumors of the heart and great vessels'' (Armed Forces Institute of Pathology: AFIP) published in 1996 [3] (   Table 2). In benign tumors, tumor were classified as tumor showing differentiation into muscle cells such as rhabdomyoma, adult cellular rhabdomyoma, hamartoma of mature cardiac myocytes, and histiocytoid cardiomyopathy. Cardiac myxoma and papillary fibroelastoma are classified as pluripotent mesenchymal origin, and cardiac fibroma and inflammatory myofibroblastic tumor were classified as tumor showing differentiation into myofibroblastic cell. Other benign tumors are vascular tissue origin as hemangioma, fat tissue origin as lipoma, and congenital cystic lesions in the atrioventricular node as cystic tumor of atrioventricular node. This classification includes relatively high incidence of benign cardiac tumors, however, tumors of low incidence such as tumors of neural cell differentiation or smooth muscle cell differentiation are not included. Most prominent differences of WHO classification from AFIP classification are classification of malignant tumors. Firstly, epithelioid hemangioendothelioma, formerly classified as benign tumor has been classified as malignant tumor, and secondarily undifferentiated sarcoma, which has been classified as tumor of unknown origin, is united to form one disease as malignant pleomorphic fibrous histiocytoma (MFH)/ undifferentiated pleomorphic sarcoma subtype. Other WHO World Health Organization features of WHO classification are malignant mesenchymoma, osteosarcoma, chondrosarcoma, and many other sarcomas were not included as an independent sarcoma, but included in MFH/undifferentiated pleomorphic sarcoma, and tumor that had been referred to as myxosarcoma specific for heart was classified as a subtype of myxoid fibrosarcoma.
Since the AFIP classification of the heart, pericardium, and great vessels has been widely used, we propose a new classification based on AFIP classification, with reference to the WHO classification and taking into account the recent findings of cell differentiations and clinical importance [6] (Table 3). Cardiac tumors are classified as benign tumors, malignant tumors, and ectopic cardiac tumors and other tumors. Benign tumors are classified into cardiac tumors and pericardial tumors. Malignant tumors are classified as tumors originated from the heart, metastatic cardiac tumors, intravascular tumors with extension to the heart, and malignant pericardial tumors. The tumors of ectopic cardiac tumors and other tumors are tumors of unknown origin, ectopic other tissue formation within the  heart, tumor-like lesions due to immunological or hematological disorders, and apparently no tumor lesion but should be differential diagnosed. IgG4-related sclerosing disease are included in this classification as a cardiac tumor, since this disorder are reported to be systemic immunological disorder and forming lesions in the salivary glands as well as pancreas and tumor-like lesion in the heart. In addition, the immunodeficiency-associated lymphoproliferative disorder due to the recent spread of AIDS has been included in this category. Thrombus is not a true tumor, and it was not included in the AFIP classification. We picked up thrombus as ''other disease'', because it is useful for routine clinical differential diagnosis when intracavitary or intravascular lesions is encountered.
Tumors of the great vessels are further rare tumors compared to the cardiac tumors. Most of them have been malignancies in the aorta, pulmonary artery, and vena cava, and the high incidence in the venous system. The classification of the tumors of great vessels is not well established because of its very low incidence and lack of pathological analyses [7]. For malignant tumor that occurs in the aorta, Iwabuchi [8] classified aortic tumors following two types, i.e., intimal or luminal type which main lesion is in the intima, and the mural type which main lesion is in the media to adventitia, since histological classification did not reflect patient prognosis, but tumor locations and shape is clinically important. In particular, the intimal type of tumor when tumor is protruding and exposed to the vessel lumen resulting strong degeneration and necrosis, is diagnosed as intimal sarcoma, because it may be difficult to diagnose pathology correctly due to poor pathological specimen.
Our new classification of tumors of the heart and great vessels are based on the ''tumors of the heart and great vessels'' AFIP [1] and the WHO classification [4]. The pathological and clinical entities of these tumors were not well established compared with other organs such as tumors of the digestive system, and the WHO classification classified only typical tumor and major cardiac tumors and tumor-like lesions. In our classification, we intended to include almost all the tumors and tumor-like lesions of the heart and great vessels for clinical use based on the idea of the authors. Since this classification is not perfect and did not based on fully pathological aspects, we sincerely hope that the more precise and useful classifications will be established in accordance with the development of studies about tumors of the heart and great vessels.

Epidemiology and incidence
The cardiovascular tumor is rarely encountered, and its incidence is very low among tumors of all organs. In the past, cardiac tumors are very difficult to diagnose before life and it was often discovered incidentally at autopsy. However, recent advances in diagnostic techniques such as echocardiography and computed tomography (CT) enabled clinical diagnosis during lifetime, and pathological diagnosis of tumor can be obtained by surgically removed tumors or biopsy. From these accumulated pathological and clinical data, it became evident that many varieties of tumors occur in the heart and great vessels as in other organs.

The incidence of cardiac tumors in autopsy
The incidence of cardiac tumors in autopsy cases has been reported from long time ago, it has been observed difference almost 100 times by the reporter from 0.33 to 0.0017 % so far as in the literatures (Table 4). This wide range of incidence may be due to changes of criteria for pathological diagnosis, transition of subjects for autopsy, and changes of diseases for autopsy [9,10]. Pollia and Gogol [11] reported the highest incidence of tumors originated from the heart as 0.33 % (154 cases) in autopsy of 46,072 cases, while Straus and Merliss [12] reported the lowest incidence as 0.0017 % (8 cases) in autopsy of 480,000 cases by summarizing the autopsy statistics of six hospitals. Reynen [13] reported the incidence as 0.021 % in 731,309 autopsy cases by summarizing the autopsy statistics from the 22 literatures. It is interesting the presence of year difference of incidence of tumors originated from the heart that incidence of the years 1915-1931 is 0.047 %, while 0.17 % in the years 1954-1979 from the report of Mayo Clinic [10,14]. In Japan, Mukai et al. [15] from National Cancer Center reported that tumors originated from the heart was found only in 1 case (0.038 %) during the year 1976-1985 among 2,649 autopsy cases who died of cancer. On the other hand, reports of cardiac tumors in children are scarce, Nadas and Ellison [16]  reported that incidence of tumors originated from the heart was 0.01 % at autopsy.
Tumors originated from the heart The incidence of tumors originated from the heart has changed over the years and the development of medicine between the recent era when the diagnostic methods and surgical resection developed and the era when most of the cardiac tumors were diagnosed by autopsy.
In the AFIP data [3,17], cardiac myxoma is the most common cardiac tumor accounting for 24-37 % of them, following angiosarcoma (7.3-8.5 %), and papillary fibroelastoma is observed (from 7.9-8.0 %) with approximately the same frequency. Benign tumors are more common in order of myxoma, papillary fibroelastoma, rhabdomyoma, fibroma, hemangioma, and cystic tumor of atrioventricular node, and malignant tumors are more common in order of angiosarcoma, unclassified sarcoma, and malignant fibrous histiocytoma (Table 5). In comparison with adults, the incidence of cardiac tumors in children is very low [3,16].
In addition, percentages of rhabdomyoma and fibroma are especially high, and histiocytoid cardiomyopathy also is relatively high, but cardiac myxoma which is the most common in adults is characterized as less common [3,18] ( Table 6). Interestingly, rhabdomyoma is considered a  AFIP Armed Forces Institute of Pathology specific tumor which in some cases disappears in the course of observation [16]. In children, malignant tumors originated from the heart are very rare, and leiomyosarcoma, unclassified sarcoma, and rhabdomyosarcoma are reported [3,16]. In this way, the susceptible age when cardiac tumors have been diagnosed is different for each tumor. According to the AFIP data [3], rhabdomyoma and teratoma occur in infancy, rhabdomyosarcoma and cardiac fibroma is common in the adolescence, mesothelioma, lipomatous hyperplasia, and papillary fibroelastoma tended to occur in the elderly [3,9,19] (Table 7). Our results of research about cardiac tumors in Japan supported by the Grant-inaid for Scientific Research from Japan Society for the Promotion of Science (JSPS: 21591793) is not similar to that of the data of AFIP for susceptible age when cardiac tumors were diagnosed. This may be due to the small number of cases in our study compared to AFIP data and recent high incidences of presentation of cardiac tumors in the elderly in recent aging society.
Cardiac tumors have been reported frequently in the regional meetings of the Japanese Association for Thoracic Surgery (JATS) and the Japanese Circulation Society (JCS). Compiling the tumor incidence by reported cases that have been reported in the meeting of regional meeting of JATS and JCS during the years 1999-2010, the most frequent benign tumor was cardiac myxoma (34.0-43.1 %), followed by papillary fibroelastoma (11.4-17.7 %), lipoma (2.4-3.4 %), and hemangioma (2.4-2.6 %) in the order [9] ( Table 8). On the other hand, frequency of the malignant cardiac tumor with the exception of malignant lymphoma was angiosarcoma (8.2-9.5 %), malignant fibrous histiocytoma (3.3-4.3 %), and leiomyosarcoma (1.9-2.2 %) in the order. Although the approximate frequency rate of cardiac tumors were similar among regional meeting of JATS and JCS, it may be possible that the same case have been reported in both meetings. However, for malignant lymphoma, different incidence between JCS: 20.4 % and JATS: 6.0 % may reflect that radiation therapy and  1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008   Modified from reference [9] JCS Japanese Circulation Society, JATS Japanese Association for Thoracic Surgery chemotherapy is the subject of treatment and surgery have been attempted to patients only for open biopsy due to failure of non-invasive tissue diagnosis or for life-saving surgery for patients suffering from heart failure due to intracavitary obstructing tumor. In addition, since the relatively rare cases tend to be reported at such regional meetings, it is plausible that these data did not reflect the actual incidence of tumor in Japan.
Regarding number of cases of surgery for cardiac tumors in Japan, there are annual statistics of JATS; since the survey began in 1986, incidence of cardiac tumor has been increasing every year. Recently, about 400-500 cases have been operated in every year, and cardiac myxoma accounts for about 70 % of them (Fig. 1).
By our research project for cardiac tumors in Japan supported by the Grant-in-aid for scientific research from Japan Society for the Promotion of Science, we send out questionnaires to the JATS-and JCS-certified 1,789 hospitals in 2010 asking the cardiac tumor incidence between January and December, 2009. As a result, 580 cases with cardiovascular tumors have been experienced in 326 hospitals, most of 389 cases (67.1 %) were benign tumors originated from the heart, following malignant tumors originated from the heart were 90 cases (15.5 %) and metastatic tumors were 75 cases (12.9 %) [9] (Table 9). In addition, 12 cases of pericardial tumor (2.1 %), and 14 cases of tumor of the great vessels (2.4 %) have been experienced. Considering the annual statistics from JATS and this clinical epidemiological study in Japan, it is Modified from reference [9] PEComa perivascular epithelioid cell tumor estimated that the tumors originated from the heart occurs near 500 cases per year. In this study, tumors originated from the heart have been reported 489 cases. Among these cases, the 390 cases (79.8 %) of benign cardiac tumors were more than malignancy, and 332 cases (67.8 %) were cardiac myxoma, followed by 46 cases of papillary fibroelastoma (9.4 %), 5 cases of rhabdomyoma (1.0 %), lipomatous hyperplasia, lipoma, granular cell tumor, paraganglioma, schwannoma, hamartoma, and perivascular epithelioid cell tumor. Eighty-eight cases (18.0 %) were malignant tumors originated from the heart, among them 43 cases (8.9 %) were malignant lymphoma, followed 9 cases (3.5 %) of  Modified from references [9] angiosarcoma, 17 cases (1.8 %) of rhabdomyosarcoma, 5 cases (1.0 %) of malignant fibrous histiocytoma, and 2 cases (0.4 %) of osteosarcoma. As of pericardial tumor, two cases of malignant mesothelioma were reported. Tumors of the great vessels were extremely rare. Pulmonary artery tumors were most frequent, among them intimal sarcoma in five cases, angiosarcoma in two cases, and one case of leiomyosarcoma. Two cases of metastatic aortic tumors (thymic carcinoma, esophageal carcinoma) were reported, and in the vena cava tumors, one case of primary angiosarcoma and three metastatic tumors were reported.

Metastatic cardiac tumors
Pathway of metastasis from other organs to the heart or pericardium are direct invasion from nearby organs such as lung, mediastinum or esophagus, distant metastasis by lymphatic metastasis or hematogenous metastasis, extension of the tumor via vena cava or pulmonary vein to the heart chamber, or combination of these routes. The incidence of metastatic cardiac tumors in autopsy cases has been reported 0.7-3.5 % and in autopsy cases of malignant tumor has been reported 1.7-14 %; thus metastatic cardiac tumors are more frequent than malignant tumors originated from the heart [20] (Table 10). Lymburner [14] reported high incidence of metastatic cardiac tumors as 52 cases (0.61 %) and malignant tumors originated from the heart as 4 cases (0.047 %) in 8,550 autopsy cases, which ratio is 13:1 in 1934.
Mukai et al. [15] reported that during a 10-year period (1976)(1977)(1978)(1979)(1980)(1981)(1982)(1983)(1984)(1985), only one case of a primary malignant mesothelioma (0.038 %) was identified among 2,649 autopsies  (15.4 %) in which heart and/or pericardium were secondarily involved with a malignant tumor from other organs. Burke indicated that if one accepts a rate of 1 to 3 % for cardiac metastases occur in autopsy, and a rate of 1 to 3 % for malignant tumors originated from the heart seen in autopsy, then the ratio of cardiac metastases to malignant tumors originated from the heart is 100:1 to 1,000:1. They suggested that this estimate is so higher than previous estimate 1:20 to 1:40; thus, a ratio that falls within the range of 100 to 1,000:1 is likely an accurate estimate of the true ratio of metastatic tumors to malignant tumors originated from the heart [3]. Since Butany et al. [21] reported that two malignant tumors originated from the heart (0.017 %) and 264 metastatic tumors (2.31 %) were identified among 11,432 autopsies (the ratio of malignant tumors originated from the heart to metastatic tumors 1:132), Burke's estimate is plausible. Lung cancer is the most high incident metastatic cardiac tumor followed by breast cancer, malignant melanoma, leukemia, and malignant lymphoma [15,21] (Table 11). In our study about cardiac tumors in Japan supported by the Grant-in-aid for scientific research revealed that among 116 metastatic tumors, direct invasion to the heart was 32 cases (27.6 %), distant metastasis from other organ cancer was 39 cases (34.5 %), and intravenous extension of the tumor was 33 cases (28.4 %) ( Table 12). As the rate of metastases to the heart and pericardium (number of cases with metastases to the heart/number of autopsy of malignancy for each 9100), malignant melanoma most frequently metastasizes to the heart (49-67.5 %), followed by germ cell tumors (43 %), leukemia (21.4-34 %), malignant lymphoma (18.4-21 %), and others [3,15] (Table 13).
Bussani et al. [22] reported the study for an autopsy of 18,751 cases, and among 7,289 cases of malignant tumor metastasis to the heart was found in 622 cases (9.1 %). Malignant pleural mesothelioma showed the highest rate (48.4 %) of metastasis, followed by malignant melanoma (27.8 %) and lung adenocarcinoma (21 %). In addition, the frequency rate of lung cancer was different in accordance with the pathology of the lung cancer, and in adenocarcinoma it was 21 %, undifferentiated carcinoma 19.5 %, squamous cell carcinoma 18.2 %, and bronchoalveolar carcinoma 9.8 %.
The metastatic site of the metastatic tumor in the heart are to the heart, pericardium, and both heart and pericardium. Mukai et al. [15] reported that among 407 cases of cardiac metastasis, metastasis to the myocardium was 169 cases (41.5 %), followed by epicardium 136 cases (33.4 %), pericardium 78 cases (19.2 %), and endocardium 24 cases (5.9 %), and Butany et al. [21] reported that among 193 cases of cardiac metastasis, metastasis to the pericardium was 127 cases (65.8 %), myocardium 56 cases (29.0 %), epicardium 48 cases (24.9 %), and endocardium 6 cases (3.1 %) [12,21] (Table 14). The differences of the incidence of metastatic cardiac tumor by reporters may be due to what kind of hospital, i.e., general hospital, cancer specialized hospital or cardiovascular specialized hospital, or whether hospital has system to perform an autopsy and department pathology or not [21]. It is also possible that the statistical results are different depending on whether to include the hematopoietic tumors such as leukemia and malignant lymphoma. While there is a report that incidence of metastatic cardiac tumor does not significantly change with time [23], Mukai et al. [15] reported increase in its incidence from 9.7 % in 1996 report to 15.4 % in 1988. In addition, according to the study of the reported cases summarized by Al-Mamgani et al. [20], its incidence prior to 1975 was 3.8 % and subsequent significant increased to 7.1 % in recent years.
Formerly, most of the metastatic cardiac tumors have been so far reported in autopsy cases. Recent advances of diagnostic imaging methods by CT, MRI, and echocardiography enabled to discover metastasis to the heart early even in the absence of symptoms related to the heart, such as arrhythmia and heart failure [24]. In addition to these development of diagnostic tools, incidence of metastatic cardiac tumors may increase further by life-prolonging effect by anti-cancer drugs .
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.